Prevalence of burnout and associated moderator factors among emergency medical services personnel: a meta-analysis.

Eur J Emerg MedJul 9, 2026 (epub)
Clinical ResearchEmergency Medicine

Garry Huang, Chin-Wang Hsu, Chao-Wei Chou et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined the prevalence of burnout among 32,841 emergency medical services (EMS) personnel, including paramedics and EMTs. The pooled prevalence of burnout was found to be 40% (95% CI: 33-49%), with significant variability across studies. The analysis included 35 studies and highlighted the need for early assessment and intervention to support mental health in this workforce.

Key findings

  • The raw prevalence of burnout among EMS personnel ranged from 5.3% to 88.8%, with a median of 36.7%.
  • The pooled prevalence of burnout was estimated at 40% (95% CI: 33-49%).
  • Mixed EMS personnel exhibited the highest burnout prevalence at 52%, compared to paramedics (41%), EMTs (36%), and firefighters (19%).
  • Personal-related burnout was most prevalent at 45%, followed by work-related (39%) and patient-related burnout (19%).

Why it matters

Understanding the prevalence of burnout in EMS personnel is crucial for developing targeted interventions that can enhance mental health support and improve overall workforce well-being, ultimately affecting the quality of care provided to patients.

Source

PubMed · PMID 42423593

Published in Eur J Emerg Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Emergency Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.